Medicine and Dentistry
Interstitial Lung Disease
100%
Idiopathic Pulmonary Fibrosis
92%
Pulmonary Fibrosis
35%
Diseases
34%
Sarcoidosis
30%
Forced Vital Capacity
28%
Diagnosis
27%
Placebo
27%
Symptom
25%
Coughing
23%
Spirometry
22%
Quality of Life
19%
Nintedanib
19%
Home Monitoring
18%
Silo-Filler's Disease
16%
Patient-Reported Outcome
15%
Clinical Trial
14%
Pulmonary Hypertension
14%
Electronic Nose
12%
Dyspnea
11%
Forced Expiratory Volume
11%
Pirfenidone
10%
Disease Exacerbation
10%
Drug Therapy
9%
Systemic Scleroderma
8%
Hypersensitivity Pneumonitis
8%
Lung Transplantation
8%
Auscultation
7%
Infection
7%
Breath Analysis
7%
Meta-Analysis
7%
Patient Referral
7%
Clinician
6%
Histamine
6%
Breathing
6%
Disease Course
5%
Chronic Obstructive Pulmonary Disease
5%
Adverse Event
5%
Cohort Effect
5%
Systematic Review
5%
Lung Artery Pressure
5%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrosing Alveolitis
76%
Lung Fibrosis
43%
Placebo
40%
Interstitial Lung Disease
35%
Sarcoidosis
35%
Disease
32%
Nintedanib
31%
Coughing
26%
Symptom
19%
Clinical Trial
13%
Lung Disease
10%
Pulmonary Hypertension
10%
Pirfenidone
10%
Lung Sarcoidosis
9%
Disease Exacerbation
9%
Dyspnea
8%
Methotrexate
8%
Coronavirinae
7%
Adverse Event
7%
Antacid Agent
7%
Infection
7%
Prednisone
7%
Autotaxin
7%
Systemic Sclerosis
7%
Side Effect
5%
Nursing and Health Professions
Sarcoidosis
20%
Fibrosing Alveolitis
19%
Spirometry
14%
Disease
13%
Interstitial Lung Disease
13%
Home Monitoring
10%
Symptom
9%
Quality of Life
9%
Lung Fibrosis
8%
Forced Vital Capacity
8%
Diagnosis
7%
Pilot Study
7%
Clinician
5%